You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases
|
|---|---|
| Published in |
Journal of Extracellular Vesicles, February 2023
|
| DOI | 10.1002/jev2.12305 |
| Pubmed ID | |
| Authors |
Guoping Li, Tianji Chen, James Dahlman, Lola Eniola‐Adefeso, Ionita C. Ghiran, Peter Kurre, Wilbur A. Lam, Jennifer K. Lang, Eduardo Marbán, Pilar Martín, Stefan Momma, Malcolm Moos, Deborah J. Nelson, Robert L. Raffai, Xi Ren, Joost P. G. Sluijter, Shannon L. Stott, Gordana Vunjak‐Novakovic, Nykia D. Walker, Zhenjia Wang, Kenneth W. Witwer, Phillip C. Yang, Martha S. Lundberg, Margaret J. Ochocinska, Renee Wong, Guofei Zhou, Stephen Y. Chan, Saumya Das, Prithu Sundd |
| Abstract |
Extracellular vesicles (EVs) carry diverse bioactive components including nucleic acids, proteins, lipids and metabolites that play versatile roles in intercellular and interorgan communication. The capability to modulate their stability, tissue-specific targeting and cargo render EVs as promising nanotherapeutics for treating heart, lung, blood and sleep (HLBS) diseases. However, current limitations in large-scale manufacturing of therapeutic-grade EVs, and knowledge gaps in EV biogenesis and heterogeneity pose significant challenges in their clinical application as diagnostics or therapeutics for HLBS diseases. To address these challenges, a strategic workshop with multidisciplinary experts in EV biology and U.S. Food and Drug Administration (USFDA) officials was convened by the National Heart, Lung and Blood Institute. The presentations and discussions were focused on summarizing the current state of science and technology for engineering therapeutic EVs for HLBS diseases, identifying critical knowledge gaps and regulatory challenges and suggesting potential solutions to promulgate translation of therapeutic EVs to the clinic. Benchmarks to meet the critical quality attributes set by the USFDA for other cell-based therapeutics were discussed. Development of novel strategies and approaches for scaling-up EV production and the quality control/quality analysis (QC/QA) of EV-based therapeutics were recognized as the necessary milestones for future investigations. |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 16% |
| United States | 4 | 13% |
| Sweden | 1 | 3% |
| Canada | 1 | 3% |
| Netherlands | 1 | 3% |
| Ireland | 1 | 3% |
| Iran, Islamic Republic of | 1 | 3% |
| Argentina | 1 | 3% |
| Taiwan | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 15 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 19 | 59% |
| Scientists | 10 | 31% |
| Science communicators (journalists, bloggers, editors) | 2 | 6% |
| Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 66 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 18% |
| Student > Bachelor | 8 | 12% |
| Student > Master | 7 | 11% |
| Researcher | 4 | 6% |
| Unspecified | 4 | 6% |
| Other | 4 | 6% |
| Unknown | 27 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 17 | 26% |
| Agricultural and Biological Sciences | 6 | 9% |
| Unspecified | 4 | 6% |
| Medicine and Dentistry | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 6 | 9% |
| Unknown | 29 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2023.
All research outputs
#1,775,896
of 25,394,764 outputs
Outputs from Journal of Extracellular Vesicles
#83
of 672 outputs
Outputs of similar age
#38,585
of 484,659 outputs
Outputs of similar age from Journal of Extracellular Vesicles
#7
of 20 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 672 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 484,659 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.